Top Factor Driving Glucagon-like Peptide 1 Market Growth in 2025: Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market

"How Are the key drivers contributing to the expansion of the glucagon-like peptide 1 market?
The global glucagon-like peptide 1 market is predicted to be bolstered by the increasing occurrence of diabetes. Diabetes characterizes a condition where there is an excess of blood sugar or blood glucose. The medical treatment of conditions such as type 2 diabetes, which could result in weight loss and better control of blood sugar, uses glucagon-like peptide 1. The National Library of Medicine, a US-based biomedical informatics and computational biology center, indicated in January 2022, that the worldwide prevalence of diabetes in individuals aged 20-79 was 10.5% (536.6 million individuals) in 2021. This figure is projected to rise to 12.2% (783.2 million people) by 2045. Consequently, the increasing occurrence of diabetes is expected to drive the glucagon-like peptide 1 market.

Get Your Glucagon-like Peptide 1 Market Report Here:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

What growth opportunities are expected to drive the glucagon-like peptide 1 market's CAGR through 2034?
In recent times, there has been a robust expansion in the glucagon-like peptide 1 market. The market size, which is expected to increase from $20.88 billion in 2024 to $22.37 billion in 2025, will exhibit a compound annual growth rate (CAGR) of 7.1%. Factors contributing to growth during the historic period include a surge in diabetes cases, an emphasis on enhanced diabetes care, patients' preference for injectable treatments, the clinical effectiveness and safety of these treatments, and progress in diabetes research.

Expectations are high for a robust expansion in the glucagon-like peptide 1 market size in the forthcoming years. The market is predicted to reach ""$31.27 billion by 2029, registering a compound annual growth rate (CAGR) of 8.7%. Factors contributing to this growth during the forecast period include the advent of oral glp-1 therapies, attention towards personalized medicine and inclusion in diabetes treatment algorithms, along with a patient-centric approach in the healthcare sector. Key trends anticipated during the forecast period encompass market proliferation in developing economies, regulatory green lights for new formulations, emphasis on personalized medicine, initiatives to enhance patient knowledge and awareness, and changes in the competitive landscape.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

What are the emerging trends shaping the future of the glucagon-like peptide 1 market?
Technological advancements are emerging as a key trend in the global glucagon-like peptide 1 market. Major players in this market are adopting new and inventive technologies to maintain their market standing. For instance, Novo Nordisk A/S, a pharmaceutical corporation based in Denmark, introduced Wegovy in March 2024 - the first and only glucagon-like peptide 1 therapy administered once weekly and designed for weight management. Wegovy, having successfully completed the STEP Phase 3a clinical trial program, exhibited a safe and well-received profile across the board. It is designed for individuals struggling with obesity to achieve and sustain weight loss.

Which growth-oriented segments of the glucagon-like peptide 1 market are leading the industry's development?
The glucagon-like peptide 1 market covered in this report is segmented -

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10830

What regions are leading the charge in the glucagon-like peptide 1 market?
North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the glucagon-like peptide 1 market?
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

What Is Covered In The Glucagon-like Peptide 1 Global Market Report?

• Market Size Forecast: Examine the glucagon-like peptide 1 market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the glucagon-like peptide 1 market for a structured understanding.
• Key Players Overview: Analyze major players in the glucagon-like peptide 1 market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the glucagon-like peptide 1 market.
• Segment Contributions: Evaluate how different segments drive overall growth in the glucagon-like peptide 1 market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the glucagon-like peptide 1 market.
• Industry Challenges: Identify potential risks and obstacles affecting the glucagon-like peptide 1 market.
• Competitive Landscape: Review strategic developments in the glucagon-like peptide 1 market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead

This release was published on openPR.